Pfizer Ibrance Breast Cancer Drug Shows Promising Results During Clinical Trial

Pfizer Ibrance Breast Cancer Drug Shows Promising Results During Clinical Trial

In this May 4, 2014 file photo, the Pfizer logo is displayed on the exterior of a former Pfizer factory in the Brooklyn borough of New York.  Pfizer is buying Hospira for approximately $15.23 billion, saying it is a good fit with its global established pharmaceutical business. Hospira Inc., based in Lake Forest, Illinois, is a provider of injectable drugs and infusion technologies.  Pfizer said Thursday, Feb. 5, 2015 that it will use its global network to help expand Hospira’s reach to Europe and key emerging markets. (AP Photo/Mark Lennihan)
In this May 4, 2014 file photo, the Pfizer logo is displayed on the exterior of a former Pfizer factory in the Brooklyn borough of New York. (AP Photo/Mark Lennihan)

 

(Tech Times) – Pfizer’s breast cancer drug Ibrance shows favorable clinical trial after facing delays due to efficacy issues.

Ibrance is also well-known as palbociclib and it is currently undergoing phase three study, which is called PALOMA-3 trial. The clinical trials have shown significant improvements in Progression-Free Survival, or PFS.

“The results of this trial are especially important because they help us understand the potential of IBRANCE to improve outcomes in patients with this difficult to treat cancer. We’re gratified to be able to stop the trial early and are engaging in discussions with health authorities regarding a regulatory path forward,” says Dr. Mace Rothenberg, the chief medical officer and senior vice president of Clinical Development and Medical Affairs of Pfizer Oncology.

The researchers suggest that Ibrance was combined with fulvestrant or Faslodex, which is made by AstraZeneca Plc that is used for blocking estrogen. The clinical trials were promising as patients taking the combination of drugs showed better results in comparison to patients who took just fulvestrant.

READ MORE